BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

American Regent, Inc. Expands Promotional Campaign For Iron Deficiency Anemia Drug Injectafer® (Ferric Carboxymaltose Injection)


1/22/2014 10:49:24 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a Daiichi Sankyo Group Company), announced today an expanded promotional campaign for Injectafer® (ferric carboxymaltose injection) in the United States. It is also announcing that Injectafer® has received a C code (C9441), which will allow health care providers to be reimbursed for administering Injectafer® to Medicare patients in the outpatient hospital setting. Injectafer® is the first high-dose, non-dextran intravenous (IV) iron for the treatment of adult patients with iron deficiency anemia (IDA) of various etiologies who have intolerance to oral iron or who have had an unsatisfactory response to oral iron. It is also indicated for treatment of IDA in adult patients who have non-dialysis dependent chronic kidney disease. With the US launch of Injectafer®, ferric carboxymaltose (the active ingredient) is now approved in more than 50 countries.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES